- Home
- MNPR vs MDXH Comparison
MNPR vs MDXH Comparison
Compare MNPR & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNPR
- MDXH
- Stock Information
- Founded
- MNPR 2014
- MDXH 2003
- Country
- MNPR United States
- MDXH Belgium
- Employees
- MNPR N/A
- MDXH N/A
- Industry
- MNPR Biotechnology: Pharmaceutical Preparations
- MDXH
- Sector
- MNPR Health Care
- MDXH
- Exchange
- MNPR Nasdaq
- MDXH Nasdaq
- Market Cap
- MNPR 113.5M
- MDXH 93.1M
- IPO Year
- MNPR 2019
- MDXH 2021
- Fundamental
- Price
- MNPR $28.54
- MDXH $1.96
- Analyst Decision
- MNPR Strong Buy
- MDXH Strong Buy
- Analyst Count
- MNPR 4
- MDXH 2
- Target Price
- MNPR $38.50
- MDXH $7.00
- AVG Volume (30 Days)
- MNPR 59.4K
- MDXH 145.0K
- Earning Date
- MNPR 11-08-2024
- MDXH 02-26-2025
- Dividend Yield
- MNPR N/A
- MDXH N/A
- EPS Growth
- MNPR N/A
- MDXH N/A
- EPS
- MNPR N/A
- MDXH N/A
- Revenue
- MNPR N/A
- MDXH $84,708,000.00
- Revenue This Year
- MNPR N/A
- MDXH $27.57
- Revenue Next Year
- MNPR N/A
- MDXH $20.09
- P/E Ratio
- MNPR N/A
- MDXH N/A
- Revenue Growth
- MNPR N/A
- MDXH 33.01
- 52 Week Low
- MNPR $1.55
- MDXH $1.55
- 52 Week High
- MNPR $38.50
- MDXH $4.44
- Technical
- Relative Strength Index (RSI)
- MNPR 60.16
- MDXH 38.10
- Support Level
- MNPR $24.00
- MDXH $1.97
- Resistance Level
- MNPR $26.52
- MDXH $2.25
- Average True Range (ATR)
- MNPR 2.42
- MDXH 0.16
- MACD
- MNPR 0.32
- MDXH -0.04
- Stochastic Oscillator
- MNPR 68.85
- MDXH 0.00
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA), and Europe.